Notably, the current group I PAK inhibitors (PAK‐5339, FRAX597, FRAX1036, and IPA‐3) are not PAK2 selective but have been shown experimentally to have direct antitumour effects [50, 51, 52] as well as ability to overcome chemoresistance [53, 54] in other cancer types. The gene discussed is PAK2; the disease is cancer.